Results filed 5 November 2026 · Market cap ₹1,977 crore · PE 33.7
GrowthTranscript read
Revenue
+38.0%
on a year ago
EBITDA
+178.7%
on a year ago
Profit to shareholders
+40.9%
on a year ago
EBITDA margin
33.4%
+3.9 pts on last quarter
Hester Biosciences reported strong Q2 FY27 performance with consolidated revenue growing 37.9% YoY to ₹97.9 crore and EBITDA margins expanding to 33.4%. Growth was led by Poultry Healthcare (+27% in Q2) and a rebound in Animal Healthcare tender execution (+34% in Q2), while international operations faced headwinds in Nepal due to delayed PPR tender procurement. Management is advancing biologicals from its newly capitalized BSL-3 facility and extending a $1 million intercompany loan to support Hester Africa.
Source: Hester Biosciences Limited’s filing to NSE, 5 November 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.
What stood out
Consolidated Q2 revenue grew 37.9% YoY to ₹97.9 crore and EBITDA rose 179.5% YoY with EBITDA margin expanding significantly to ~33-35%SourcePriya Gandhi stated: 'At a consolidated level, revenue grew by 38% in Q2 and 13% in H1... PAT increased by 44% in Q2' (original page 4) and 'Gross profit margin stood at 78% in both Q2 and H1... EBITDA margin stood at 35% across both periods' (original page 4).
Loan amendment with Gates Foundation in Q1 materially distorted H1 consolidated profits via an exceptional accounting gainSourcePriya Gandhi noted: 'H1 consolidated profitability includes an exceptional accounting gain recognized in Q1 following the amendment of Hester Africa's loan agreement with the Gates Foundation. This contributed significantly to the reported H1 profit growth and should be viewed separately from the performance of the business' (original page 4).
Nepal PPR eradication program procurement failed to scale as originally envisagedSourcePriya Gandhi stated: 'In Nepal, the anticipated procurement under international PPR eradication programs has not materialized at the scale originally envisaged. We are evaluating on how best to adapt the business to the environment' (original page 6).
Guidance
Metric
Guidance
Period
Poultry segment base performanceSource'We foresee that poultry will continue at the worst at this base, cannot go down, and it can only improve, and we will add on ruminant vaccine.' (Rajiv Gandhi, original page 12)
Poultry baseline expected to be maintained or improved in H2
H2 FY27
Tailwinds
Robust growth in Poultry Healthcare division driven by institutional business and wider market reachSourcePoultry division revenue increased by 27% in Q2 and 37% in H1, supported by penetration into institutional clients and new regions (Priya Gandhi, original pages 4, 11).
Rebound in Animal Healthcare Q2 revenue executionSource'Animal Healthcare recorded a revenue growth of 34% in Q2, supported primarily by increased tender execution.' (Priya Gandhi, original page 5)
Gross margin and operating discipline supporting strong EBITDA marginsSource'Gross profit margin stood at 78% in both Q2 and H1... EBITDA margin stood at 35% across both periods, reflecting higher sales and disciplined cost management.' (Priya Gandhi, original page 4)
Headwinds
Animal Healthcare H1 performance dragged by Q1 weaknessSource'H1 revenue remained 14% below the corresponding period of the previous year, reflecting lower sales in Q1.' (Priya Gandhi, original page 5)
Underperformance of Nepal operations due to lack of international PPR tender uptakeSource'In Nepal, the anticipated procurement under international PPR eradication programs has not materialized at the scale originally envisaged.' (Priya Gandhi, original page 6)
Elongated R&D timelines and potential capex due to strict regulatory complianceSource'...regulatory requirements in animal health care are becoming increasingly rigorous... can extend the development and approval time lines' (Priya Gandhi, original pages 5-6) and 'may be chances for us to do a little bit more investment, tweak our technologies, which can require some capex' (original page 9).
New businesses and products
other · Power purchase agreement signed
Captive Solar Power Project
Expected benefit
Improve energy cost efficiency and increase renewable energy use
Investment
3-megawatt group captive solar project
Source'We also signed a power purchase agreement for a 3-megawatt group captive solar project to improve energy cost efficiency and increase renewable energy use.' (Priya Gandhi, original page 6)
capacity expansion · Capitalized and in process of commercial utilization
BSL-3 Laboratory Commercialization and Biological Pipeline
Expected benefit
Expand product offerings suited to BSL-3 laboratory across poultry and animal health
Risks
Regulatory requirements becoming more rigorous, which can extend approval and development timelines
Source'Profitability improved despite higher depreciation following the capitalization of the BSL-3 laboratory and fill/finish facility... Our development program includes products suited to our recently capitalized infrastructure, particularly the BSL-3 laboratory.' (Priya Gandhi, original pages 4-5)
new geography · Ongoing export market entry and product registrations
Hester Africa Export Expansion and Ruminant Vaccines
Expected benefit
Supply large animal ruminant vaccines to export markets within Africa, Middle East, and Asia
Risks
Operational and financial sustainability challenges requiring parent funding
Timeline
Ongoing
Investment
Intercompany loan of $1 million provided by Hester India
Source'We have entered into quite a few export markets within the continent of Africa as well as Middle East and Asia by registering products that are only manufactured in our Africa plant.' (Priya Gandhi, original page 8)
Things to check
Ongoing capital infusion into Hester Africa to fortify operations and sustain businessSourceAnkit noted Hester India providing an intercompany loan of $1 million to Hester Africa, which Rajiv Gandhi explained as needed to 'fortify the operations over there' (original pages 7-8).
Failure of the anticipated demand under international PPR eradication programs in NepalSource'In Nepal, the anticipated procurement under international PPR eradication programs has not materialized at the scale originally envisaged.' (Priya Gandhi, original page 6)
How the call went
The call was concise and covered basic division performance, but management was noticeably guarded regarding product-level figures (such as H9N2), specific capex plans, and exact usage of funds lent to Hester Africa.
Specific or vague
Management provided divisional revenue growth rates and high-level margin metrics, but declined to provide volume or revenue breakdowns for key products like H9N2, exact export figures, or specifics on African fund usage.
Candour
Management candidly admitted the underperformance in Nepal and that H1 profit growth was heavily distorted by the Gates Foundation loan amendment gain.
The hard questions
Analysts probed on specific sales and volume contributions of H9N2, capitalization of ₹10 crore intangible assets under development, utilization of the $1 million intercompany loan to Africa, and whether foreign subsidiaries are profitable. Management gave high-level or vague answers on product breakups and loan usage details.
What analysts pressed on
Export revenue share and execution timeline.
Africa business funding needs and the purpose of the $1M intercompany loan.
Breakdown of growth between core vaccines, H9N2, and non-vaccine animal health products.
Capex outlook given heightened regulatory standards.
Intangible assets under development of ₹10 crore sitting on the balance sheet.
Answers that sidestepped
Refusal to disclose volume or revenue metrics for the H9N2 vaccine ('I will not be in a position really to give you any detailed volume led or any revenue indication on just H9N2' - Priya Gandhi, original page 11).
Vague response regarding the exact deployment of the $1M loan to Hester Africa ('fortification consists of good administration backed by the required finances... it is an overall requirement' - Rajiv Gandhi, original page 8).
Dismissing questions regarding whether specific foreign subsidiaries are making losses ('there is no specific separate entity which is making any loss' - Priya Gandhi, original page 10).
Numbers against the story
Management emphasized strong operational performance and doubling of PAT; however, they acknowledged that consolidated H1 net profit was heavily boosted by an exceptional gain from a loan amendment with the Gates Foundation rather than pure core operating growth. Consolidated Q2 EBITDA margin showed sharp YoY expansion to 33.4% (vs 16.5% YoY), aligning with management's commentary about operational discipline and favourable product mix.
Figures: the company’s results filing with NSE, linked under the table.
Notes written by gemini-3.8-flash from the documents above on 15 November 2026. They summarise what the company said and can contain mistakes: check the source passage before relying on a point. Not investment advice.